![]() |
|
|
The Department of Nutrition and Food Science and the Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48202
2To whom correspondence should be addressed. E-mail: ndhurand{at}sun.science.wayne.edu.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: obesity infection
| Background |
|---|
|
|
|---|
An adequate understanding of the pathogens as etiological factors is needed for better management of obesity. A new perspective about the infectious etiology of obesity may initiate additional research in the field to assess the contribution of pathogens in human obesity and possibly to prevent or treat the obesity of infectious origin. The following is a review of the role of various pathogens that have been implicated in obesity. Two of the pathogens, avian adenovirus SMAM-1 and a human adenovirus Ad-36, have been associated with human obesity and, therefore, will be discussed in detail.
Canine distemper virus.
Lyons et al. (11)
published the first report of obesity
induced by a virus, which showed canine distemper virus
(CDV)3, from the family of paramyxoviruses,
induced obesity in mice (11)
. Body weight, fat cell size
and fat cell number increased significantly in Swiss albino mice
experimentally infected with CDV. Of the mice surviving CDV infection,
hyperplastic and hypertrophic obesity was observed 620 wk after
infection in
26% of the animals when infected intracerebrally and
in 16% of the animals when infected intraperitoneally with the virus.
The obese mice had reduced circulating catecholamine levels. The
phenomenon of CDV-induced obesity in mice has been subsequently
confirmed and is believed to be due to virus-induced hypothalamic
damage (12
15)
. Recently, Bernard et al.
(16)
showed downregulation of expression of the leptin
receptor in the hypothalami of CDV-infected obese mice and
suggested it as the cause of the observed weight gain. Bernard et al.
(16)
feel that the results demonstrate a "hit-and-run"
type of relation between CDV and the expression of obesity, i.e., the
initial viral impact in the hypothalamus may initiate changes that
would continue to promote obesity in animals even after the acute
infection has subsided. CDV is not considered a human pathogen, and the
contribution of CDV to human obesity is unknown. However, measles virus
is a human virus closely related to the CDV and belongs to the
paramyxovirus family. Animal experiments showing the effect of measles
virus on adiposity are unavailable.
Rous-associated virus-7.
Carter et al. (4)
reported a syndrome characterized by
stunting, hyperlipidemia, hypercholesterolemia and obesity due to
Rous-associated virus-7 (RAV-7) infection in chickens. Inoculation
of 10-d-old chick embryos with RAV-7 via a chorioallantoic route
produced fat deposition around crop and abdominal fat pads in the adult
birds (4)
. The results could be replicated by similar
inoculations with the serum obtained from RAV-7infected adult birds
(5)
. The RAV-7induced obesity syndrome and pathology is
dependent on route of inoculation. Intravenous inoculation of 1-d-old
chickens with RAV-7 did not produce stunting and obesity.
RAV-7 produced fatty and yellow-colored livers, hepatomegaly,
anemia and immune suppression. The livers were 6.2 and 2.4% of the
body weight in the RAV-7infected and -uninfected birds, respectively.
These disease manifestations were seen within 34 wk after hatching of
the eggs. The stunting and hyperlipidemia were the most striking
features of the syndrome observed in the RAV-7infected chickens. The
mean body weight of 50-d-old RAV-7infected chickens was 194 g,
as compared with 515 g in the age-matched control group.
Several chickens from the RAV-7 group had serum triglycerides levels
>2,000 mg/dL, and one chicken had serum triglycerides >14,000 mg/dL.
Food intake was not different for the RAV-7infected and -uninfected
control groups. Also, dietary fat content did not influence the degree
of lipid accumulation in the birds. RAV-7infected chickens have
decreased levels of thyroid hormones, which was a suggested cause of
the observed obesity and hyperlipidemia (4)
. Although this
work was done >17 y ago, its relevance to human obesity is unknown.
Borna disease virus.
Borna disease virus (BDV) was the third virus to be implicated in
obesity. Gosztonyi and Ludwig (17)
have described in
detail the pathogenesis of BDV. BDV is a single, negative-stranded
RNA virus that primarily targets the nervous system but also replicates
in many other organs. In nature, BDV infections occur in horses and
sheep and cause encephalomyelitis, but experimental infection may be
produced in birds, rodents and primates. BDV infection produces a
syndrome of obesity in rats, characterized by lympho-monocytic
inflammation of the hypothalamus, hyperplasia of pancreatic islets and
elevated serum glucose and triglycerides (10)
.
Gosztonyi and Ludwig (10)
state that expression of
BDV-induced obesity syndrome varies with the age of the animals at
the time of inoculation, the genetic background of the host and the
virus strain used. Rats infected as newborns with BDV (passaged and
harvested in rabbits) show progressive neurological disease after
1216 mo. On the other hand, weanling or adult rats similarly
inoculated with BDV develop acute encephalitis and die within 14 mo.
Some of these rats survive the infection and develop marked obesity
(18)
. BDV affects several areas in the brain, and a
central mechanism is a strong possibility (perhaps due to a
virus-induced hypothalamic damage). The exact mechanisms of
BDV-induced obesity remain unknown.
Although BDV was not considered to be a human pathogen, BDV antigen and
antibodies have been seen in humans as well (10)
. BDV is
associated with schizophrenia and mental depression in humans
(19
,20)
, which is responsive to treatment by amantadine,
an antiviral (21
,22)
. Further research is needed to
determine if BDV contributes to the depression observed in obese
individuals.
Scrapie agent.
Scrapie is a neurodegenerative disease of a long incubation period,
known to occur in sheep and goats. Although the key features of scrapie
infections are abnormal behavior and motor dysfunction, mice
(23)
and hamsters (24)
experimentally
infected with scrapie agents also developed obesity. The
obesity-promoting characteristic is a function of the scrapie
strain but not mouse strain. Regardless of the mouse strain tested,
scrapie strain ME7 induced obesity. The effect was not observed with
scrapie strains 139A or 22L (25)
. Vacuolation caused by
ME7 is in the forebrain of the mouse, whereas, 22L and 139A cause
vacuolation in the cerebellum and white matter, respectively
(25)
. It is not known if the difference in the
obesity-promoting potential of the agents is linked to the
differences in the brain lesions observed. Kim et al. (26)
demonstrated that adrenalectomy prevents ME7-induced obesity in mice,
and suggest that scrapie-induced obesity depends on an effect of
scrapie on the hypothalamic-pituitary-adrenal axis.
SMAM-1 avian adenovirus.
In India, Ajinkya (27)
identified SMAM-1 avian adenovirus
as the cause of an epidemic that had killed thousands of poultry in
India in the early 1980s. SMAM-1 is serologically similar to chick
embryo lethal orphan (CELO) avian adenovirus present in the U.S.
(27)
. Information about the presence of SMAM-1 in the U.S.
is not available.
Three-week-old chickens experimentally inoculated with SMAM-1 developed
excessive visceral fat and paradoxically lower levels of serum lipids
compared with the uninfected controls (6
,7)
. A third group
of uninoculated chickens sharing the room with inoculated chickens
(in-contact group) also developed the obesity syndrome, evidently from
airborne virus particles (6
,7)
. In addition to adiposity,
the SMAM-1infected birds developed pale and enlarged liver and
kidneys, hepatic fatty infiltration and congestion, and basophilic
intranuclear inclusion bodies in hepatocytes (6
,7)
. Food
intake was similar for the three groups, and the final body weight for
the inoculated group was lower than that for the control group. Total
carcass fat was not determined in these experiments, but the visceral
fat was greater by 53 and 33% in the inoculated and in-contact
groups, respectively.
Subsequently, Dhurandhar et al. (28)
screened 52 obese
humans for antibodies to SMAM-1 virus using agar-gel-precipitation
test. Approximately 20% of the subjects had antibodies to SMAM-1. The
antibody-positive subjects had significantly greater body weight
(95.1 ± 2.1 vs. 80.1 ± 0.6 kg, P < 0.02)
and BMI (35.3 ± 1.5 vs. 30.7 ± 0.6
kg/m2, P < 0.001) compared with
the antibody-negative group. Moreover, the SMAM-1
antibodypositive group had
15% lower serum cholesterol and 60%
lower serum triglycerides. This is the first report of an association
of a virus with human obesity.
It is unknown if the SMAM-1 antibodies in humans had developed in
response to a past infection with the virus or due to a human
adenovirus antigenically similar to SMAM-1. These data are in contrast
to conventional wisdom that avian adenoviruses do not infect humans and
human adenoviruses do not cross-react with avian adenoviruses
(15)
. Experiments described below show that a human
adenovirus, Ad-36, can infect chickens and induce adiposity.
Human adenovirus Ad-36.
Adenoviruses are naked DNA viruses with icosahedral symmetry and a
diameter of 6580 nm. In humans, adenoviruses are frequently
associated with acute upper respiratory tract infections, and they may
also cause enteritis and conjunctivitis. Adenoviruses can easily be
isolated from nasal swabs or from feces. Adenovirus infections are
transmitted via respiratory, fomite, droplet, venereal and
fecal-oral routes. There are 50 different types of human
adenoviruses listed with the American Type Culture Collection.
Adenovirus type 36 (Ad-36) does not cross-react with most other
human adenoviruses (29
,30)
; therefore, it is antigenically
unique. Ad-36 was first isolated in 1978 in Germany in the feces of a
6-y-old girl suffering from diabetes and enteritis (30)
.
In four separate experiments, chickens and mice were inoculated with
human adenovirus Ad-36. These animals developed a syndrome of increased
adipose tissue and paradoxically low levels of serum cholesterol and
triglycerides (9)
. This syndrome was not seen in the
chickens inoculated with avian adenovirus CELO. Sections of the brain
and hypothalamus of Ad-36inoculated animals did not show any overt
histopathological changes. Ad-36 DNA could be detected in adipose
tissue, but not skeletal muscles of animals, for as long as 16 wk after
Ad-36 inoculation [Table 1
(9)
].
|
2.5 times and the I-R group had 1.8 times greater visceral fat.
The two infected groups (I-D and I-R) also showed a significant
reduction in cholesterol, and the I-D group had a significant
reduction in serum triglycerides. These data confirmed the previous
findings that Ad-36 produces adiposity and paradoxical reductions in
serum lipids. In addition, the study fulfilled Kochs postulate by
transmitting disease (adiposity) from infected animals (I-D group) to a
new set of animals (I-R group). Human studies.
Human serum samples obtained from obese (BMI
27
kg/m2) and nonobese volunteers from three
different sites (Wisconsin, Florida and New York) were screened for the
presence of Ad-36 antibodies using serum neutralization assays.
Prevalence of Ad-36 antibodies in three sites pooled together was 5%
for the nonobese and 30% for the obese subjects (33
,34)
.
At each of the sites, the antibody-positive obese subjects had
significantly lower serum cholesterol compared with the
antibody-negative obese subjects from the respective site
(33
,34)
. Thus, antibody-positive humans had lower
serum cholesterol and triglycerides levels, like the animals
experimentally infected with Ad-36.
These data show an association of Ad-36 antibodies with human obesity
but do not establish a causative relationship. Because of ethical
reasons, the definitive experiment of injecting humans with Ad-36 to
determine the role of Ad-36 in human obesity is unlikely to ever be
conducted. Relevance of Ad-36 to human obesity would continue to be
open to question until perhaps the experiments are conducted in a model
more relevant to humans. Recent preliminary data have suggested the
suitability of two nonhuman primate models, rhesus monkeys and
marmosets, to study the adiposity promoting potential of Ad-36
(35
,36)
. More animal and human research is needed to
establish the contribution of Ad-36 in human obesity.
Infections and obesity: conjectures.
Although a causative role of certain infections in obesity is a
relatively novel concept, adipose tissue involvement with modulators
and mediators of immune response is well documented. For example,
Cousin et al. (37)
showed that preadipocytes function like
macrophages and possess phagocytic and microbicidal activity.
Adipocytes also participate in the immune response. Leptin, an
adipocyte-secreted hormone involved in body weight regulation, also
enhances proliferation and activation of human circulating T-cells
and stimulates cytokine production (38)
. In addition to
leptin-directed modulation of cytokine release, adipocytes
themselves secrete various cytokines (39
,40)
and, in turn,
preadipocytes and adipocytes are subject to cytokine-directed
modulations (41
,42)
. With such an extensive interaction
between the immune system and the adipose tissue, expansion of the
latter in response to certain infections is conceivable. For instance,
macrophage colonystimulating factor, which promotes the production of
macrophages, is also secreted by adipocytes and, when overexpressed in
vivo, induces significant adipose tissue hyperplasia (43)
.
It is unknown if the obesity-promoting pathogens stimulate
macrophage colonystimulating factor production that leads to the
growth of adipose tissue.
A body of evidence shows association of obesity with cytokines and
markers of inflammation. Elevated levels of interleukin-6
(44)
and C-reactive proteins (45)
are
observed in obese individuals. Interestingly, Duncan et al.
(46)
showed that markers of inflammation can predict
weight gain in middle-aged adults. A 3-y follow-up of >13,000
men and women showed an adjusted odds ratio of a large weight gain
(>90th percentile) of 1.65 for those in the highest quartile for
baseline fibrinogen levels as compared with the lowest quartile
(46)
. Higher odds ratios for large weight gain were also
seen with other markers of inflammation. The authors suggested that a
mild inflammatory response process plays a role in stimulation of
weight gain (46)
. The above-mentioned cross-sectional
and prospective studies show association of obesity with the presence
of a chronic, mild state of inflammation. It remains to be determined
if the noted inflammation was in response to certain infections.
| CONCLUSION |
|---|
|
|
|---|
Clearly, not every case of obesity is of infectious origin. However, if a few pathogens can cause obesity, there may be more awaiting discovery. These data give a new perspective to the etiology of obesity and raise the possibility of infection as a contributing factor for obesity in some humans. When such a relationship between pathogens and human obesity is well established, vaccines or antimicrobial agents may be employed to prevent or treat some forms of obesity.
| FOOTNOTES |
|---|
3 Abbreviations: BDV, Borna disease virus; CDV,
canine distemper virus; CELO, chick embryo lethal orphan; RAV-7,
Rous-associated virus-7. ![]()
| LITERATURE CITED |
|---|
|
|
|---|
1. Bray G. A. (1979) Obesity in America 1979 NIH Publication 79359 Washington .
2. Sclafani A. (1984) Animal models of obesity: classification and characterization. Int. J. Obesity 8:491-508.[Medline]
3. Atkinson R. L., Dhurandhar N. V. & Taylor K. (1997) Production of obesity in mice with a human virus. Int. J. of Obesity 21:S36.
4.
Carter J. K., Ow C. L. & Smith R. E. (1983) Rous-Associated virus type 7 induces a syndrome in chickens characterized by stunting and obesity. Infect. Immun. 39:410-422.
5. Carter J. K., Garlich J. D., Donaldson W. T. & Smith R. E. (1983) Influence of diet on a Retrovirus induced obesity and stunting syndrome. Avian Dis 27:317-322.[Medline]
6. Dhurandhar N. V., Kulkarni P. R., Ajinkya S. M. & Sherikar A. A. (1990) Avian adenovirus leading to pathognomic obesity in chickens. J. Bombay Vet. College 2:131-132.
7. Dhurandhar N. V., Kulkarni P. R., Ajinkya S. M. & Sherikar A. A. (1992) Effect of adenovirus infection on adiposity in chickens. Vet. Microbiol. 31:101-107.[Medline]
8. Dhurandhar N. V. & Atkinson R. L. (1996) Development of obesity in chickens after infection with a human adenovirus. Obesity Res 4:24S.
9. Dhurandhar N. V., Israel B. A., Kolesar J. M., Mayhew G. F., Cook & M. E. & Atkinson R. L. (2000) Adiposity in animals due to a human virus. Int. J. Obesity 24:989-996.
10. Gosztonyi G. & Ludwig H. (1995) Borna disease: Neuropathology and pathogenesis. Current Topics in Microbiol. Immunol. 190:39-73.
11.
Lyons M. J., Faust I. M., Hemmes R. B., Buskirk D. R., Hirsch J. & Zabriskie J. B. (1982) A virally induced obesity syndrome in mice. Science 216:82-85.
12. Bernard A., Zwingelstein G., Meister R. & Fabian Wild T. (1988) Hyperinsulinemia induced by canine distemper virus infection of mice and its correlation with the appearance of obesity. Comp. Biochem. Physiol. 91B:691-696.
13. Bernard A., Fevre-Montange M., Giraudon P., Hardin H., Fabian Wild T. & Belin M. F. (1991) Localization of viral proteins and RNA in hypothalamus of mice infected by canine distemper virus. Virology 313:545-551.
14. Bernard A., Fevre-Montange M., Bencsik A., Giraudon P., Fabian Wild T., Confavreux C. & Belin M. F. (1993) Brain structures selectively targeted by canine distemper virus in a mouse model infection. J. Neuropath. Exp. Neuro. 52:471-480.[Medline]
15. McFerran J. B., Adair B. & Connor T. J. (1975) Adenoviral antigens (CELO, QBV, GAL). Am. J. Vet. Res. 36:527-534.[Medline]
16.
Bernard A., Cohen R., Khuth S. T., Vedrine B., Verlaeten O., Akaoka H., Giraudon P. & Belin M. E. (1999) Alteration of the leptin network in late morbid obesity induced in mice by brain infection with canine distemper virus. J. Virology 73(9):7317-7327.
17. Fabricant C. G., Fabricant J., Minick C. R. & Litrenta M. M. (1983) Herpesvirus induced atherosclerosis in chickens. Federation Proc 42:2476-2479.[Medline]
18. Gosztonyi G., Kao M., Bode L. & Ludwig H. (1991) Obesity syndrome in experimental infection of rats with Borna disease virus. Clin. Neuropathol. 10:33-34.
19. Chen C. H., Chiu Y. L., Shaw C. K., Tsai M. T., Hwang A. L. & Hsiao K. J. (1999) Detection of Borna disease virus RNA from peripheral blood cells in schizophrenic patients and mental health workers. Mol. Psychiatry 4(6):566-571.[Medline]
20. Chen C. H., Chiu Y. L., Wei F. C., Koong F. J., Liu H. C., Shaw C. K., Hwu H. G. & Hsiao K. J. (1999) High seroprevalence of Borna virus infection in schizophrenic patients, family members and mental health workers in Taiwan. Mol. Psychiatry 4(1):33-38.[Medline]
21. Dietrich D. E., Bode L., Spannahuth C. W., Lau T., Huber T. J., Brodhun B., Ludwig H. & Emrich H. M. (2000) Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar. Disord. 2(1):65-70.[Medline]
22. Ferszt R., Kuhl K. P., Bode L., Severus E. W., Winzer B., Berghofer A., Beelitz G., Brodhun B., Muller-Oerlinghausen B. & Ludwig H. (1999) Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with borna disease virus infection. Pharmacopsychiatry 32(4):142-147.[Medline]
23. Kim Y. S., Carp R. I., Callahan S. M. & Wisniewski H. M. (1987) Scrapie-induced obesity in mice. J. Infect. Dis. Aug; 156(2):402-405.
24. Carp R. L., Kim Y. S. & Callahan S. M. (1990) Pancreatic lesions and hypoglycemia-hyperinsulinemia in scrapie- injected hamsters. J. Infect. Dis. 161(3):462-466.[Medline]
25. Carp R. L., Meeker H., Sersen E. & Kozlowski P. (1998) Analysis of the incubation periods, induction of obesity and histopathological changes in senescence-prone and senescence-resistant mice infected with various scrapie agents. J. Gen. Virol. 79(Pt 11):2863-2869.[Abstract]
26. Kim Y. S., Carp R. L., Callahan S. M. & Wisniewski H. M. (1988) Adrenal involvement in scrapie-induced obesity. Proc. Soc. Exp. Biol. Med. 189(1):21-27.[Abstract]
27. Ajinkya S. M. (1985) Final Technical Report, ICAR 1985:13-43 Red and Blue Cross Publishing Bombay, India .
28. Dhurandhar N. V., Kulkarni P. R., Ajinkya S. M., Sherikar A. A. & Atkinson R. L. (1997) Screening of human sera for antibody against avian adenovirus. Obesity Res 5:464-469.[Medline]
29. Hierholzer J. C., Wigand R., Anderson L. J., Adrian T. & Gold J.W.M. (1988) Adenoviruses from patients with AIDS: A plethora of serotypes and a description of five new serotypes of subgenus D (Types 4347). J. Infectious Dis. 158:804-813.[Medline]
30. Wigand R., Gelderblom H. & Wadell G. (1980) New human adenovirus (candidate adenovirus 36), a novel member of subgroup D. Arch. Virology 64:225-233.[Medline]
31. Dhurandhar N. V., Israel B. A., Kolesar J. M., Mayhew G., Cook M. E. & Atkinson R. L. (2001) Transmissibility of adenovirus-induced adiposity in a chicken model. Int. J. Obesity 25:990-996.
32. Kolesar J. M., Miller J. A., Dhurandhar N. V. & Atkinson R. L. (2000) Direct quantification of AD-36 adenovirus DNA by capillary electrophoresis with laser-induced fluorescence. J. Chromatog. B. 744:1-8.
33. Atkinson R. L., Dhurandhar N. V., Allison D. B., Bowen R. & Israel B. A. (1998) Evidence for an association of an obesity virus with human obesity at three sites in the United States. Int. J. Obesity 22:S57.
34. Dhurandhar N. V., Augustus A. & Atkinson R. L. (1997) Evidence for an association of a virus with obesity in humans. FASEB J 3:A230.
35. Atkinson R. L., Dhurandhar N. V., Abbott D. H. & Darken N. (2000) Weight gain and reduced serum lipids in non- human primates due to a human virus. Int. J. Obesity suppl 1:S39.
36. Dhurandhar N. V., Bradley S. M., Kemnitz J. W. & Atkinson R. L. (1999) Antibodies to human adenovirus Ad- 36 are associated with body weight changes in monkeys. FASEB J 13(4):A369.
37.
Cousin B., Munoz O., Andre M., Fontanilles A. M., Dani C., Cousin J. L., Laharrague P., Casteilla L. & Penicand L. (1999) A role for preadipocytes as macrophage-like cells. FASEB J 13:305-312.
38. Martin-Romero C., Santoz-Alvarez J., Goberna R. & Sanchez-Margalet V. (2000) Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell. Immunol. 199(1):15-24.[Medline]
39.
Fried S. K., Bunkin D. A. & Greenberg A. S. (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot differences and regulation by glucocorticoids. J. Clin. Endocrin. Metab. 83(3):847-850.
40. Sewter C. P., Digby J. E., Blows F., Prins J. & ORahilly S. (1999) Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J. Endocrinol. 163(1):33-38.[Abstract]
41. Kras K. M., Hausman D. B. & Martin R. J. (2000) Obesity Res 8(2):186-93.[Medline]
42. Gregoire F., De Broux N., Hauser N., Heremans H., Van Damme J. & Remacle C. (1992) Interferon-gamma and interleukin-1 beta inhibit adipoconversion in cultured rodent preadipocytes. J. Cell Physiol. 151(2):300-309.[Medline]
43. Levine J. A., Jensen M. D., Eberhardt N. L. & OBrien T. (1998) Adipocyte macrophage colony- stimulating factor is a mediator of adipose tissue growth. J. Clin. Invest. 101(8):1557-1564.[Medline]
44. Roytblat L., Rachinsky M., Fisher A., Greemberg L., Shapira Y., Douvdevani A. & Gelman S. (2000) Raised interleukin-6 levels in obese patients. Obesity Res 8:673-675.[Medline]
45.
Visser M., Bouter L. M., McQuillan G. M., Wener M. H. & Harris T. M. (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135.
46. Duncan B. B., Schmidt M. I., Chambless L. E., Folsom A. R., Carpenter M. & Heiss G. (2000) Fibrinogen, other putative markers of inflammation, and weight gain in middle- aged adults-The ARIC study. Obesity Res 8:279-286.[Medline]
This article has been cited by other articles:
![]() |
M. S. Desruisseaux, Nagajyothi, M. E. Trujillo, H. B. Tanowitz, and P. E. Scherer Adipocyte, Adipose Tissue, and Infectious Disease Infect. Immun., March 1, 2007; 75(3): 1066 - 1078. [Full Text] [PDF] |
||||
![]() |
N. Kolakowski The Obesity Virus? DOC News, January 1, 2005; 2(1): 13 - 13. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||